Qualcomm suppressed competition in the market for cellphone chips and used its position to impose excessive licensing fees, a U.S. judged ruled.Technologyread more
Morgan Stanley caused a stir with its "bear case" scenario of $10. Now, Citi is getting in on the act.Investingread more
Treasury Secretary Steven Mnuchin is scheduled to testify before the House Financial Services Committee on Wednesday about the international financial system.Politicsread more
Target's e-commerce sales also surged 42%, as shoppers increasingly turned to its curbside pickup service for online orders, something Amazon can't offer.Retailread more
Stock markets are slowly healing from the worst of the month's trade war sell-off, and one under-the-surface indicator suggests the S&P 500 might completely recover before...Trading Nationread more
Treasury Secretary Steven Mnuchin said nothing is scheduled yet for the U.S. to go to Beijing for the next round of trade talks.Marketsread more
Homeowners are taking advantage of lower interest rates, rushing to refinance their mortgages before rates potentially turn higher again.Real Estateread more
The U.S. Justice Department's Antitrust Division staff has recommended the agency sue to block T-Mobile US's $26 billion acquisition of smaller rival Sprint, according to two...Technologyread more
Lowe's shares plummeted 8% before the bell Wednesday after the company posted mixed fiscal first-quarter results and cut its forecast for the year, as higher costs weighed on...Retailread more
It may be years from visiting your neighborhood, but a walking robot is part of Ford's vision for how its autonomous vehicles will deliver packages.Autosread more
Brazilian makeup brand Natura Cosmeticos agreed to buy Avon Products, according to two media reports early on Wednesday.Retailread more
Peachtree Corners GA, May 13, 2015 (GLOBE NEWSWIRE) -- GeneCure Biotechnologies, a clinical stage biotechnology company developing novel human vaccines based on its patented lentiviral delivery platform technology, announced today that its Chief Executive Officer, Dr. Frank Tung presented a talk entitled A Randomized, Double blinded, Placebo Controlled Trial of a Therapeutic HIV Vaccine at the 18th annual meeting of the American Society of Gene and Cell Therapy in New Orleans, Louisiana, USA.
Although current antiretroviral therapies (ART) are effective in controlling viral load in HIV infected patients, the virus typically re-emerges soon after secession of ART. Dr. Tung’s presentation focused on GeneCure’s ongoing therapeutic HIV vaccine (HIVAX) clinical trial investigating its potential of controlling viral load in HIV-infected patients. HIVAX was tested for safety and immunogenicity in 15 HIV-infected patients undergoing ART. Patients were randomized 2 to 1 to receive HIVAX or placebo (as control). The primary endpoints were safety and immunogenicity. HIVAX was well tolerated without severe adverse effects and was highly immunogenic in all HIVAX vaccinated HIV patients. Robust CD8+ T cell responses, which play a critical role for recognition and killing of HIV infected cells, were stimulated in all HIVAX vaccinated patients. Following the vaccination, ten patients who received HIVAX suspended ART for 12 weeks in order to assess their ability to control virus re-emergence. Median viral load at the end of the 12-week ART interruption was significantly lower (6.7 folds and 25 folds) than two control cohorts (unvaccinated) described in previously published studies. Furthermore, three HIVAX vaccinated patients extended ART interruption for up to 2 years and still maintain stable CD4+ T cell counts and low viral loads.
HIVAX shows great potential as a therapeutic HIV vaccine to reduce the dependency and adverse effects associated with ART. Based on this promising data, GeneCure is currently recruiting more HIV patients for subsequent clinical trials.
About GeneCure Biotechnologies
GeneCure Biotechnologies is a private biotechnology company developing novel human vaccines based on its patented lentiviral delivery platform. The mission of the company is to develop safe, potent and simple to use human vaccines to manage chronic viral infections and cancers. GeneCure’s lead product is a therapeutic HIV vaccine that is currently being tested as a first-in-human, proof-of-concept therapy for HIV infected patients. Other products in the pipeline include therapeutic Hepatitis C and B vaccines for chronic infected patients. GeneCure also possesses in-house GMP manufacture capabilities for the production of clinical grade materials.
This news release contains forward-looking statements, which are based on company’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in the statements due to a variety of factors, over which GeneCure Biotechnologies has no control. These forward-looking statements speak only as of the date hereof. GeneCure Biotechnologies disclaims any obligation to update these forward-looking statements.
GeneCure Biotechnologies, email:email@example.com, telephone:1-770-263-7508
Source: GeneCure Biotechnologies